Hager Investment Management Services LLC Invests $145,000 in Gilead Sciences, Inc. (NASDAQ:GILD)

Hager Investment Management Services LLC bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, according to its most recent disclosure with the SEC. The firm bought 1,575 shares of the biopharmaceutical company’s stock, valued at approximately $145,000.

Several other institutional investors and hedge funds have also recently modified their holdings of GILD. Algert Global LLC purchased a new stake in shares of Gilead Sciences in the 2nd quarter worth about $254,000. AMF Tjanstepension AB increased its stake in shares of Gilead Sciences by 14.7% in the 3rd quarter. AMF Tjanstepension AB now owns 400,819 shares of the biopharmaceutical company’s stock worth $33,645,000 after acquiring an additional 51,390 shares in the last quarter. Czech National Bank increased its stake in shares of Gilead Sciences by 6.8% in the 3rd quarter. Czech National Bank now owns 253,618 shares of the biopharmaceutical company’s stock worth $21,263,000 after acquiring an additional 16,209 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Gilead Sciences by 53.7% in the 3rd quarter. GAMMA Investing LLC now owns 15,273 shares of the biopharmaceutical company’s stock worth $1,281,000 after acquiring an additional 5,333 shares in the last quarter. Finally, Diversified Trust Co increased its stake in shares of Gilead Sciences by 1.4% in the 3rd quarter. Diversified Trust Co now owns 33,436 shares of the biopharmaceutical company’s stock worth $2,803,000 after acquiring an additional 449 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Stock Performance

GILD opened at $97.99 on Wednesday. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The company has a market cap of $122.12 billion, a price-to-earnings ratio of 1,088.78, a PEG ratio of 1.37 and a beta of 0.18. The company’s 50 day moving average is $92.58 and its 200 day moving average is $86.14. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $99.45.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. The company had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm’s revenue was up 7.0% compared to the same quarter last year. During the same quarter last year, the firm posted $2.29 earnings per share. On average, equities research analysts predict that Gilead Sciences, Inc. will post 4.34 EPS for the current year.

Insider Buying and Selling

In other Gilead Sciences news, insider Merdad Parsey sold 164,211 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the transaction, the insider now owns 80,801 shares of the company’s stock, valued at $7,427,227.92. The trade was a 67.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the transaction, the director now directly owns 8,920 shares in the company, valued at $815,198.80. This represents a 43.21 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 572,824 shares of company stock valued at $53,611,715. 0.29% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research analysts recently issued reports on GILD shares. Maxim Group lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Mizuho increased their price target on shares of Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research note on Thursday, November 21st. Royal Bank of Canada reiterated a “sector perform” rating and issued a $84.00 price target on shares of Gilead Sciences in a research note on Monday. Sanford C. Bernstein began coverage on shares of Gilead Sciences in a research note on Thursday, October 17th. They set an “outperform” rating and a $105.00 price objective for the company. Finally, Wolfe Research began coverage on shares of Gilead Sciences in a research note on Friday, November 15th. They set an “outperform” rating and a $110.00 price objective for the company. Eleven equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $98.39.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.